Nyxoah (NASDAQ:NYXH) versus Atrion (NASDAQ:ATRI) Head to Head Contrast

Atrion (NASDAQ:ATRI) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Atrion and Nyxoah, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrion	0	0	0	0	N/A
Nyxoah	0	1	5	0	2.83

Nyxoah has a consensus target price of $20.60, suggesting a potential upside of 93.97%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than Atrion.

Profitability

This table compares Atrion and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atrion	11.46%	8.07%	7.37%
Nyxoah	-993.28%	-38.58%	-31.24%

Earnings and Valuation

This table compares Atrion and Nyxoah’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrion	$169.33 million	4.11	$19.41 million	$11.03	35.81
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.68)	-6.32

Atrion has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

66.2% of Atrion shares are owned by institutional investors. 22.7% of Atrion shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Atrion has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Summary

Atrion beats Nyxoah on 8 of the 11 factors compared between the two stocks.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.